Hypermarcas (OTCMKTS:HYPMY) Share Price Passes Below 50 Day Moving Average - Should You Sell?

Key Points

• Hypermarcas stock fell below its fifty-day moving average, trading at $4.23 despite a higher average price of $4.72.
• Scotiabank recently upgraded the company to a "strong-buy" rating, indicating positive analyst sentiment.
• The company announced a dividend of $0.0345 per share, yielding 281.0%, with the payout date set for January 8th.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) shares passed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $4.72 and traded as low as $4.23. Hypermarcas shares last traded at $4.23, with a volume of 742 shares traded.

Wall Street Analysts Forecast Growth

Separately, Scotiabank raised Hypermarcas to a "strong-buy" rating in a report on Thursday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Strong Buy".

Hypermarcas Price Performance

The stock has a market capitalization of $2.68 billion, a price-to-earnings ratio of 20.13 and a beta of 0.77. The company has a quick ratio of 0.80, a current ratio of 1.26 and a debt-to-equity ratio of 0.63. The business has a 50-day simple moving average of $4.71 and a two-hundred day simple moving average of $4.03.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported $0.12 earnings per share for the quarter. Hypermarcas had a return on equity of 6.19% and a net margin of 11.28%.

Hypermarcas Announces Dividend

The firm also recently announced a dividend, which will be paid on Friday, January 8th. Shareholders of record on Tuesday, July 1st will be given a dividend of $0.0345 per share. This represents a yield of 281.0%. The ex-dividend date of this dividend is Monday, June 30th. Hypermarcas's dividend payout ratio is presently 57.14%.

About Hypermarcas

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.